American Century Companies Inc. Buys 23,170 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

American Century Companies Inc. raised its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 3.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 743,140 shares of the company’s stock after purchasing an additional 23,170 shares during the quarter. American Century Companies Inc. owned approximately 1.50% of Mineralys Therapeutics worth $8,695,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Catalys Pacific LLC bought a new position in Mineralys Therapeutics during the fourth quarter worth about $79,073,000. RA Capital Management L.P. boosted its stake in Mineralys Therapeutics by 52.6% in the 1st quarter. RA Capital Management L.P. now owns 4,850,984 shares of the company’s stock valued at $62,626,000 after purchasing an additional 1,672,508 shares during the period. Affinity Asset Advisors LLC acquired a new position in Mineralys Therapeutics in the 1st quarter valued at $4,234,000. Franklin Resources Inc. increased its position in Mineralys Therapeutics by 55.4% during the 4th quarter. Franklin Resources Inc. now owns 699,467 shares of the company’s stock worth $6,015,000 after buying an additional 249,450 shares during the period. Finally, SR One Capital Management LP lifted its holdings in shares of Mineralys Therapeutics by 12.4% during the first quarter. SR One Capital Management LP now owns 2,016,822 shares of the company’s stock worth $26,037,000 after buying an additional 222,222 shares in the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Thursday, August 15th.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock opened at $11.45 on Tuesday. The firm has a market cap of $568.48 million, a PE ratio of -5.23 and a beta of 1.93. The stock’s fifty day moving average price is $11.95 and its two-hundred day moving average price is $12.43. Mineralys Therapeutics, Inc. has a one year low of $5.85 and a one year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter last year, the business earned ($0.31) earnings per share. Sell-side analysts expect that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $13.14, for a total transaction of $141,346.98. Following the completion of the transaction, the chief financial officer now directly owns 247,611 shares in the company, valued at $3,253,608.54. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Brian Taylor Slingsby sold 550,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $13.05, for a total value of $7,177,500.00. Following the sale, the director now directly owns 8,644,579 shares in the company, valued at approximately $112,811,755.95. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $13.14, for a total transaction of $141,346.98. Following the sale, the chief financial officer now directly owns 247,611 shares in the company, valued at $3,253,608.54. The disclosure for this sale can be found here. In the last 90 days, insiders sold 577,028 shares of company stock valued at $7,536,774. Company insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.